Preview

Антибиотики и Химиотерапия

Расширенный поиск

Новые данные о молекулярных мишенях тамоксифена, отличных от рецепторов эстрогенов, и их клиническая значимость

Полный текст:

Аннотация

Тамоксифен - первый таргетный препарат, который по-прежнему занимает лидирующую позицию в лечении рака молочной железы. Экспериментальные работы последних лет раскрывают всё новые и новые биологические эффекты при воздействии тамоксифена на опухолевые клетки. Данная публикация является продолжением опубликованного в 2012 г. обзора данных литературы, демонстрирующих многообразие эффектов тамоксифена, не связанных с его взаимодействием с рецепторами эстрогенов. Так, выявлен обширный спектр мишеней препарата, которые являются ключевыми точками сигнальных каскадов, активирующих пролиферацию клеток, определяют агрессивность течения опухолевого процесса и чувствительность к химиотерапии. Описаны клинические исследования применения тамоксифена, основанием для которых явилось воздействие препарата на мишени, отличные от рецепторов эстрогенов. Кроме того, в обзор включены данные о противовирусной, противобактериальной, противогрибковой и противопаразитарной активности тамоксифена.

Об авторах

Т. А. Богуш
ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России
Россия


Б. Б. Полежаев
ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России
Россия


Е. А. Дудко
ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России
Россия


Е. А. Богуш
ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России
Россия


В. Ю. Кирсанов
ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России
Россия


Б. Е. Полоцкий
ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России
Россия


С. А. Тюляндин
ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России
Россия


М. И. Давыдов
ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России
Россия


Список литературы

1. Bogush T., Dudko E., Bogush E. et al. Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev2012; 6: 2: e15.

2. Balça-Silva J., Matias D., do Carmo A. et al. Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines. Biochim Biophysic Acta 2015; 1850: 4: 722-732.

3. Yang L., Yuan X., Wang J. et al. Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-i activity in vitro. Oncol Lett 2015; 10: 1: 473-478.

4. Couldwell W.T., Hinton D.R., Surnock A.A. et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clinical cancer research: an Official J American Association for Cancer Research 1996; 2: 4: 619-622.

5. Chamberlain M.C., Kormanik P.A. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol 1999; 56: 6: 703-708.

6. Mastronardi L., Puzzilli F., Couldwell W. T. et al. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neuro-Oncol 1998; 38: 1: 59-68.

7. Tang P., Roldan G., Brasher P. M. et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neuro-Oncol 2006; 78: 3: 311-316.

8. Cristofori A., Carrabba G., Lanfranchi G. et al. Continuous tamoxifen and dose-dense temozolamide in recurrent glioblastoma. Anticancer Res 2013; 33: 8: 3383-3389.

9. Kohli L., Kaza N., Coric T. et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res 2013; 73: 14: 4395-4405.

10. Xie X., Wu M. Y., Shou L. M. et al. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway. Oncol Lett 2015; 9: 2: 837-844.

11. Keating J.J., Johnson P.J., Cochrane A.M. et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Brit J Cancer 1989; 60: 5: 789-792.

12. Theve N.O., Pousette A., Carlström K. Adenocarcinoma of the pancreas-a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol 1983; 9: 3: 193-197.

13. Wong A., Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer 1993; 71: 7: 2200-2203.

14. Morita S., Motohara T., Ogawa K., Horimi T. Hormone therapy using tamoxifen in unresectable carcinoma of the pancreas-preliminary study. Nihon Igaku Höshasen Gakkai zasshi. Nipp Acta Radiol 1992; 52: 12: 1686-1688.

15. Lamy R., Conroy T., Brunaud L., Bresler L. Tamoxifen for metastatic pancreatic adenocarcinoma: a complete response. Gastroenterol Clin Biol 2001; 25: 10: 912-913.

16. Wenger F.A., Zieren H.U., Jacobi C.A., Müller J.M. Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen. Langenbecks Archiv Für Chirurgie. Supplement. Kongressband 1998; 115: 1348-1350.

17. Rosenberg L., Barkun A.N., Denis M.H., Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995; 75: 1: 23-28.

18. Patel B.M., Desai V.J. Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy. Pharmacol Reports 2014; 66: 2: 264-272.

19. Kuo J.R., Wang C.C., Huang S.K., Wang S.J. Tamoxifen depresses glutamate release through inhibition of voltage-dependent Ca2+ entry and protein kinase Ca in rat cerebral cortex nerve terminals. Neurochem Internation 2012; 60: 2: 105-114.

20. Steckert A.V., Valvassori S.S., Mina F. et al. Protein kinase C and oxidative stress in an animal model of mania. Curr Neurovascul Res 2012; 9: 1: 47-57.

21. Armani F., Andersen M. L., Galduróz J.C. Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology 2014; 231: 4: 639-649.

22. Smith C.P., Oh J.D., Bibbiani F. et al. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology 2007; 52: 2: 515-526.

23. Li Z, Wang N., Fang J. et al. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Oncol Reports 2012; 27: 6: 1879-1886. Выполнено при поддержке РФФИ (гранты 15-04-06991-а и 16-34-01049-мол-а) и гранта Президента Российской Федерации МК-7709.2016.7.

24. Shim J.S., Li R. J., Lv J. et al. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. Cancer Lett 2015; 362: 1: 106-115.

25. Garvin S., Nilsson U.W., Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Brit J Cancer 2005; 93: 9: 1005-1010.

26. Morad S.A., Cabot M.C. Tamoxifen regulation of sphingolipid metabolism-therapeutic implications. Biochim Biophys Acta 2015; 1851: 9: 1134-1145.

27. Morad S.A., Madigan J.P., Levin J.C. et al. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochem Pharmacol 2013; 85: 8: 1057-1065.

28. Ribeiro M.P., Santos A.E., Custodio J.B. Mitochondria: the gateway for tamoxifen-induced liver injury. Toxicology 2014; 323: 10-18.

29. Li Z., Chen J., Lei T., Zhang H. Tamoxifen induces apoptosis of mouse microglia cell line BV-2 cells via both mitochondrial and death receptor pathways. J Huazhong Univer Science Technol. Medical Sciences 2012; 32: 2: 221-226.

30. Todorova V.K., Kaufmann Y., Luo S., Klimberg V.S. Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol 2011; 67: 2: 285-291.

31. Hwang J.J., Kim H.N., Kim J. et al. Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. BioMetals 2010; 23: 6: 997-1013.

32. Cho K.S., Yoon Y.H., Choi J.A. et al. Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells. Invest Ophthalmol Visual Sci 2012; 53: 9: 5344-5353.

33. Prather P.L., FrancisDevaraj F., Dates C.R. et al. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Com 2013; 441: 2: 339-343.

34. Herrera J.L., Diaz M., Hernandez-Fernaud J.R. et al. Voltage-dependent anion channel as a resident protein of lipid rafts: post-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease. J Neurochem 2011; 116: 5: 820-827.

35. Pawar P., Ma L., Byon C.H. et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res: Official J Amer Assoc Cancer Res 2009; 15: 4: 1288-1296.

36. Jing G., Yuan K., Turk A.N. et al. Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis. Lab Investigat; J Techn Meth Pathol 2011; 91: 6: 896-904.

37. Cimica V., Smith M.E., Zhang Z. et al. Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer 2010; 10: 634.

38. Perez B., Henriquez C., Sarmiento J. et al. Tamoxifen as a new therapeutic tool for neutrophilic lung inflammation. Respirology 2016; 21: 1: 112-118.

39. Sarmiento J., Perez B., Morales N. et al. Apoptotic effects of tamoxifen on leukocytes from horse peripheral blood and bronchoalveolar lavage fluid. Vet Res Com 2013; 37: 4: 333-338.

40. Mao J., Yuan J., Wang L. et al. Tamoxifen inhibits migration of estrogen receptor-negative hepatocellular carcinoma cells by blocking the swelling-activated chloride current. J Cell Physiol 2013; 228: 5: 991-1001.

41. Ribeiro M.P., Silva F.S., Paixâo J. et al. The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells. Europ J Pharmacol 2013; 715: 1-3: 354-362.

42. Mao Z., Zhou J., Luan J. et al. Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomed Pharmacother 2014; 68: 2: 179-183.

43. Nicolao M.C., Elissondo M.C. et al. In vitro and in vivo effects of tamoxifen against larval stage Echinococcus granulosus. Antimicrob Agents Chemother 2014; 58: 9: 5146-5154.

44. Miguel D.C., Yokoyama-Yasunaka J.K., Andreoli W.K. et al. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of para-sitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother 2007; 60: 3: 526-534.

45. Miguel D.C., Zauli-Nascimento R.C., Yokoyama-Yasunaka J.K. et al. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother 2009; 63: 2: 365-368.

46. Butts A., Koselny K., Chabrier-Rosello Y. et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio 2014; 5: 1: e00765-00713.

47. Zhang X., Fang Y., Jaiseng W. et al. Characterization of tamoxifen as an antifungal agent using the yeast Schizosaccharomyces pombe model organism. Kobe J Med Sci 2015; 61: 2: E54-63.

48. Jang W.S., Kim S., Podder B. et al. Anti-mycobacterial activity of tamoxifen against drug-resistant and intra-macrophage Mycobacterium tuberculosis. J Microbiol Biotechnol 2015; 25: 6: 946-950.

49. Murakami Y., Fukasawa M., Kaneko Y. et al. Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle. Microb Infect/Institut Pasteur 2013; 15: 1: 45-55.

50. Jordan V.C. Tamoxifen as the first successful targeted therapy in cancer: the gift that kept on giving. Breast Cancer Manag 2014; 3: 4: 321-326.

51. Singh M.N., Martin-Hirsch P.L., Martin F.L. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med Sci Monitor: Internat Med J Exper Clin Res 2008; 14: 9: RA144-148.


Для цитирования:


Богуш Т.А., Полежаев Б.Б., Дудко Е.А., Богуш Е.А., Кирсанов В.Ю., Полоцкий Б.Е., Тюляндин С.А., Давыдов М.И. Новые данные о молекулярных мишенях тамоксифена, отличных от рецепторов эстрогенов, и их клиническая значимость. Антибиотики и Химиотерапия. 2016;61(3-4):41-49.

For citation:


Bogush T.A., Polezhaev B.B., Dudko E.A., Bogush E.A., Kirsanov V.Yu., Polotsky B.E., Tjuljandin S.A., Davydov M.I. New Data on Molecular Targets of Tamoxifen Besides Estrogen Receptors, Their Clinical Significancy. Antibiotics and Chemotherapy. 2016;61(3-4):41-49. (In Russ.)

Просмотров: 47


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0235-2990 (Print)